Catabasis Pharmaceuticals Announces Positive Top – Line Results from Part A of the MoveDMD Trial , a Phase 1 / 2 Trial of CAT – 1004 for the Treatment of Duchenne Muscular Dystrophy
You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.
